The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis CReportar como inadecuado




The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Infectious Diseases

, 4:4

First Online: 13 February 2004Received: 06 September 2003Accepted: 13 February 2004

Abstract

BackgroundNon-organ-specific autoantibodies are found in a considerable number of anti-HCV positive patients. Previous studies investigated the clinical relevance of these antibodies in patients treated with interferon monotherapy, but not combination therapies.

MethodsAnti-nuclear, anti-smooth muscle, anti-mitochondrial, anti-neutrophil-cytoplasmatic and anti-liver-kidney microsomal antibodies were determined in 78 consecutive anti-HCV positive patients by indirect immunofluorescence. The presence of these antibodies was related to demographic variables and to the outcome of antiviral combination therapy with interferon-α and ribavirin in 65 patients.

ResultsIn our study, positivity for autoantibodies was associated with higher alanine aminotransferase levels and higher mean values for HCV-RNA p < 0.01. Furthermore, negativity for non-organ-specific autoantibodies was associated with a favourable treatment outcome of combination therapy with at least one negative RT-PCR for HCV-RNA during treatment OR 4.65, 95% CI 1.31 to 16.48, p = 0.02. ANA and SMA staining patterns and titers were not correlated to treatment response. With multiple logistic regression analysis, positivity for autoantibodies and HCV genotype were independently associated with outcome of antiviral combination therapy p = 0.02.

ConclusionsThe absence of non-organ-specific autoantibodies might indicate a significantly higher chance for viral clearance in response to combination therapy for chronic hepatitis C infection. Therefore, despite of an overall higher treatment response, the addition of the immunomodulatory drug ribavirin could accentuate immunological differences that affect treatment outcome and might have been less obvious in earlier studies analysing interferon monotherapy.

KeywordsAntiviral therapy chronic hepatitis C interferon-α non-organ-specific autoantibodies ribavirin Electronic supplementary materialThe online version of this article doi:10.1186-1471-2334-4-4 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Hermann E Wasmuth - Christian Stolte - Andreas Geier - Christoph G Dietrich - Carsten Gartung - Johann Lorenzen - Siegfrie

Fuente: https://link.springer.com/







Documentos relacionados